Aspen Aerogels, Inc. (NYSE:ASPN) Receives Average Rating of “Buy” from Analysts

Shares of Aspen Aerogels, Inc. (NYSE:ASPN) have been given an average recommendation of “Buy” by the ten analysts that are covering the company, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $29.70.

ASPN has been the topic of a number of research reports. Barclays initiated coverage on shares of Aspen Aerogels in a research report on Tuesday, August 6th. They set an “overweight” rating and a $27.00 target price on the stock. B. Riley raised shares of Aspen Aerogels to a “strong-buy” rating in a research report on Tuesday, June 25th. TD Cowen raised their price target on shares of Aspen Aerogels from $36.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, August 20th. HC Wainwright raised their price target on shares of Aspen Aerogels from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Benchmark restated a “buy” rating and issued a $14.00 price target on shares of Aspen Aerogels in a report on Thursday, August 8th.

Aspen Aerogels Trading Up 5.0 %

NYSE ASPN opened at $23.10 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.82 and a current ratio of 3.46. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -2,307.69 and a beta of 2.16. The company’s 50-day simple moving average is $25.63 and its two-hundred day simple moving average is $24.10. Aspen Aerogels has a one year low of $6.62 and a one year high of $33.15.

Aspen Aerogels (NYSE:ASPN) last posted its earnings results on Wednesday, August 7th. The construction company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.16. The business had revenue of $117.80 million for the quarter, compared to the consensus estimate of $101.99 million. Aspen Aerogels had a net margin of 0.39% and a return on equity of 0.74%. The company’s revenue for the quarter was up 144.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.22) EPS. Equities analysts forecast that Aspen Aerogels will post 0.21 EPS for the current fiscal year.

Insiders Place Their Bets

In other Aspen Aerogels news, CEO Donald R. Young sold 63,355 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the sale, the chief executive officer now owns 483,640 shares of the company’s stock, valued at approximately $14,523,709.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Aspen Aerogels news, CEO Donald R. Young sold 63,355 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the sale, the chief executive officer now owns 483,640 shares of the company’s stock, valued at approximately $14,523,709.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Ricardo C. Rodriguez sold 32,465 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $30.14, for a total transaction of $978,495.10. Following the completion of the sale, the chief financial officer now directly owns 20,790 shares in the company, valued at $626,610.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is owned by insiders.

Institutional Trading of Aspen Aerogels

Several large investors have recently made changes to their positions in ASPN. Driehaus Capital Management LLC raised its position in Aspen Aerogels by 130.4% during the second quarter. Driehaus Capital Management LLC now owns 2,156,789 shares of the construction company’s stock worth $51,439,000 after acquiring an additional 1,220,724 shares during the period. American Century Companies Inc. raised its position in Aspen Aerogels by 562.3% during the second quarter. American Century Companies Inc. now owns 770,729 shares of the construction company’s stock worth $18,382,000 after acquiring an additional 654,350 shares during the period. Millennium Management LLC acquired a new position in Aspen Aerogels during the second quarter worth $9,339,000. Hood River Capital Management LLC raised its position in Aspen Aerogels by 12.2% during the first quarter. Hood River Capital Management LLC now owns 3,300,443 shares of the construction company’s stock worth $58,088,000 after acquiring an additional 357,895 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in Aspen Aerogels during the second quarter worth $8,340,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.